Philips, Immunetrics Unite to Target Infectious Disease

Under the joint development agreement, Philips Research and Immunetrics will investigate the combination of advanced bioinformatics and computer modeling to identify opportunities to reduce the incidence and improve the management of systemic infection, a major complicating factor among many critically ill patients, say the companies.

Philips currently owns a 29 percent stake in Immunetrics, a biosimulation company specializing in the computational modeling of pathophysiology and treatment.